There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type | HazMat fee for 500 gram (Estimated) |
Excepted Quantity | USD 0.00 |
Limited Quantity | USD 15-60 |
Inaccessible (Haz class 6.1), Domestic | USD 80+ |
Inaccessible (Haz class 6.1), International | USD 150+ |
Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |
Structure of Pyridostigmine bromide
CAS No.: 101-26-8
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Pyridostigmine Bromide is a reversible cholinesterase inhibitor to treat myasthenia gravis.
Synonyms: Pyridostigmine (bromide); Ro 1-5130; Pyridostigmine Br, Pyridostigmine
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 101-26-8 |
Formula : | C9H13BrN2O2 |
M.W : | 261.12 |
SMILES Code : | C[N+]1=CC=CC(OC(N(C)C)=O)=C1.[Br-] |
Synonyms : |
Pyridostigmine (bromide); Ro 1-5130; Pyridostigmine Br, Pyridostigmine
|
MDL No. : | MFCD00079283 |
InChI Key : | VNYBTNPBYXSMOO-UHFFFAOYSA-M |
Pubchem ID : | 7550 |
GHS Pictogram: |
![]() ![]() |
Signal Word: | Danger |
Hazard Statements: | H300+H310+H330-H317-H410 |
Precautionary Statements: | P260-P280-P284-P301+P310-P302+P350-P304+P340-P310 |
Class: | 6.1 |
UN#: | 2811 |
Packing Group: | Ⅱ |
Target |
|
In Vitro:
Concentration | Treated Time | Description | References |
Colonic myenteric plexus neurons and glia | 250 µM | 3 hours | To investigate the effects of PB and PEA on the activity of enteric neurons and glia. Results showed that PB pretreatment significantly reduced glial Ca2+ responses to PEA (61.0% decrease) and shifted the signaling mechanisms between neurons and glia from TRPV1-dependent to CB1 receptor- and PPARα-dependent pathways. | Neuropharmacology. 2020 Nov 15;179:108264 |
Rat neural progenitor cells | 200 µM | 6 days | To evaluate the effect of PY on cell viability, results showed PY did not affect cell viability at 200 μM | Neurochem Res. 2015 Oct;40(10):2091-101 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
Adult male Sprague Dawley rats | Acute diisopropylfluorophosphate (DFP) intoxication model | Intramuscular injection | 0.1 mg/kg | Single dose, 30 minutes before DFP injection | To evaluate the effect of PB pretreatment on survival and brain AChE activity in DFP-intoxicated rats. Results showed no significant effect of PB pretreatment on 24-hour survival or brain AChE activity. | Neurotoxicology. 2019 Jul;73:81-84 |
Wistar rats | Myocardial infarction model | Drinking water administration | 0.14 mg/mL | Daily administration for 12 weeks | To evaluate the effects of PYR alone or combined with exercise on left ventricle dimensions and function, baroreflex sensitivity, autonomic parameters, and systemic and tissue inflammatory profile after myocardial infarction. Results showed that PYR alone or combined with exercise improved the deleterious effects of MI, with additional benefits in skeletal muscle anti-inflammatory state when combined with resistance training. | Front Physiol. 2018 Feb 12;9:53 |
Rats | Gulf War Illness model | Oral gavage | 1.3 mg/kg | Once daily for 14 days | To evaluate the effects of pyridostigmine bromide and stress on immune function and cholinergic neurochemistry. Results showed that pyridostigmine bromide and stress interact to enhance immune responses and alter cholinergic neurochemistry. | Brain Behav Immun. 2019 Aug;80:384-393 |
Male Sprague Dawley rats | Gulf War Illness (GWI) model | Oral gavage | 1.3 mg/kg | Once daily for 14 days | To assess the long-term effects of pyridostigmine bromide and repeated restraint stress on the cholinergic anti-inflammatory pathway. Results showed that PB treatment led to enhanced cholinergic responses and paradoxical increases in pro-inflammatory cytokine release in the prefrontal cortex and hippocampus. | Neurobiol Stress. 2022 Apr 15;18:100446 |
Sprague Dawley rats | Gulf War Illness model | Oral gavage | 1.3 mg/kg | Once daily for 14 days | To investigate the effects of PB and repeated restraint stress (RRS) on glutamatergic neurochemistry, showing that PB and stress interacted to produce brain-region specific effects on glutamate neurochemistry. | Neurobiol Stress. 2019 Dec 31;12:100210 |
Rats | Gulf War Illness model | Oral gavage | 1.3 mg/kg | Once daily for 14 days | To evaluate the effects of pyridostigmine bromide and stress on cognitive function in a model of Gulf War Illness. Results showed that PB-treated rats exhibited hippocampal-dependent memory deficits at a delayed timepoint. | Brain Behav Immun. 2023 Oct;113:248-258 |
Mice | Anti-muscle-specific kinase (MuSK) myasthenia gravis model | Subcutaneous minipump | 16 mg/kg/day | Continuous for 7–9 days | Pyridostigmine treatment exacerbated the anti-MuSK-induced reductions in postsynaptic acetylcholine receptor density and endplate potential (EPP) amplitude. | J Physiol. 2013 May 15;591(10):2747-62 |
Male C57BL/6J mice | Gulf War Illness model | Subcutaneous injection | 2 mg/kg | Once daily for 14 days | To evaluate the long-term effects of pyridostigmine bromide on behavior and neuroinflammation in a Gulf War Illness model. Results showed that pyridostigmine bromide, in combination with other chemicals, led to hyperactivity, impaired sensorimotor function, and altered gait in mice. | Brain Behav Immun Health. 2022 Nov 8;26:100553 |
Mice | Pressure overload heart failure model | Subcutaneous osmotic pump | 2-10 mg/kg/day | Once daily for 28 days | To study the effects of PYR on cardiac function and rhythmicity in heart failure mice, results showed PYR improved cardiac contractile performance and rhythmic activity | J Cell Mol Med. 2021 May;25(10):4637-4648 |
Mice | Rosa26-DTMlc2v-Cre mouse model | Subcutaneous osmotic pump | 3 mg/kg/d | Continuous administration for 7 days, followed by 3-5 days post-DT injection | To investigate the effect of pyridostigmine on inflammatory responses following myocardial injury. Results showed that pyridostigmine treatment significantly reduced mortality, cardiac inflammation, and infiltration of MHC-IIloCCR2+ monocytes in DT-injected Rosa26-DTMlc2v-Cre mice, and decreased CCL2/7 mRNA and protein expression. | JCI Insight. 2019 Jun 4;5(14):e128961 |
C57BL/6J mice | Chronic Chagasic cardiomyopathy mouse model | Oral | 30 mg/kg | Daily for 30 days | To assess the effects of pyridostigmine bromide on electrocardiographic, autonomic, histopathological, immunoinflammatory, and parasitological parameters in chronic Chagas disease in mice. Results showed that pyridostigmine bromide significantly reduced myocardial inflammatory infiltration, fibrosis, and hypertrophy, accompanied by a decrease in serum IFN-γ levels, suggesting a shift toward an anti-inflammatory immune response. | Mediators Inflamm. 2014;2014:475946 |
Sprague Dawley rats | Cardiac hypertrophy induced by abdominal aorta constriction | Oral | 31 mg/kg/day | Once daily for 8 weeks | Pyridostigmine increased acetylcholine levels by inhibiting acetylcholinesterase, significantly attenuated cardiac hypertrophy, improved cardiac function, inhibited the CaN/NFAT3/GATA4 pathway, and suppressed Orai1/STIM1 complex formation. | J Cell Mol Med. 2017 Sep;21(9):2106-2116 |
Spontaneous hypertensive rats (SHRs) | Acute myocardial infarction model | Gavage | 40 mg/kg | Once daily for seven days | Pyridostigmine treatment increased parasympathetic tone, reduced M1/M2 macrophage ratio, decreased TNF levels in heart and spleen, and improved cardiac remodeling. | Sci Rep. 2021 May 5;11(1):9563 |
Spontaneously hypertensive rats | Spontaneously hypertensive rat model | Oral (via drinking water) | 5 mg/kg/day and 15 mg/kg/day | Daily administration for 2 weeks | To evaluate the effects of pyridostigmine bromide on hemodynamic, cardiac morphofunctional, and cardiovascular autonomic adaptations in spontaneously hypertensive rats. Results showed that pyridostigmine bromide reduced BP and HR, increased vagal participation in cardiac autonomic tonic balance, and improved cardiac function parameters. | Sci Rep. 2021 Aug 25;11(1):17141 |
C57BL/6 mice | Gulf War Illness model | Drinking water | 90 μg/mL | 7 consecutive days | To evaluate the long-term effects of PB on gastrointestinal motility and neuroimmune function. Results showed that PB exposure alone did not cause significant long-term changes at 5 months but dramatically altered the effects of subsequent PEA exposure, leading to significant changes in gut motility, ENS function, and immune responses, which were sex-dependent. | Neuropharmacology. 2020 Nov 15;179:108264 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT03619759 | - | Recruiting | August 31, 2019 | Korea, Republic of ... More >> Ajou university school of medicine Recruiting Suwon, Gyeonggi-do, Korea, Republic of, 16377 Contact: In Kyong Yi, MD Less << | |
NCT00624663 | Rivastigmine Toxicity | Not Applicable | Completed | - | Israel ... More >> Tel Aviv Sourasky Medical Center Tel Aviv, Israel Tasmc Clinical Research Center Tel-Aviv, Israel, 64239 Less << |
NCT03468452 | - | Completed | - | - | |
NCT02070198 | Female Infertility ... More >> Poor Responder Less << | Phase 4 | Unknown | December 2014 | Italy ... More >> Bioroma Recruiting Rome, Italy, 00197 Contact: Mauro Schimberni +39063334266 bioroma@bioroma.net Principal Investigator: Mauro Schimberni Less << |
NCT00004332 | - | Completed | - | - | |
NCT01727193 | Myasthenia Gravis | Phase 3 | Recruiting | January 2020 | China, Guangdong ... More >> the first affiliated hospital,SUN YAT-SEN UNIVERSITY Recruiting GuangZhou, Guangdong, China, 510000 Contact: Liu Wei bin, dean 086-020-887755766 ext 8281 ranliuz@163.com Principal Investigator: Liu Wei bin, dean Less << |
NCT02601508 | Neuromuscular Blockade | Not Applicable | Unknown | August 2017 | Korea, Republic of ... More >> Chonnam University Hwasun Hospital Not yet recruiting Hwasun, Korea, Republic of, 519-763 Contact: Chanhong Park, BsC +82-61-379-7598 cnuhpch@naver.com Sub-Investigator: Seongheon Lee, MD, PhD Sub-Investigator: Inje Kim, BsC Sub-Investigator: Shi Young Chung, MD Principal Investigator: Seongwook Jeong, MD, PhD Less << |
NCT00995722 | Ocular Myasthenia Gravis | Phase 3 | Terminated(Slow recruitment ra... More >>te) Less << | - | United States, Connecticut ... More >> Yale University New Haven, Connecticut, United States, 06510 United States, Florida University of Miami Miami, Florida, United States, 33136 United States, Kansas University of Kansas Medical Center Kansas City, Kansas, United States, 66160 United States, New York University at Buffalo, Buffalo General Medical Center Buffalo, New York, United States, 14203 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Texas University of Texas Southwestern Medical Center Dallas, Texas, United States, 75390 United States, Vermont University of Vermont Burlington, Vermont, United States, 05401 United States, Virginia University of Virginia Charlottesville, Virginia, United States, 22908 Canada, Alberta University of Alberta Hospital Edmonton, Alberta, Canada, T6G 2P4 Canada, Ontario Toronto General Hospital Toronto, Ontario, Canada, M5G 2C4 Less << |
NCT00223691 | Autonomic Failure ... More >> Orthostatic Hypotension Less << | Phase 1 | Completed | - | United States, Tennessee ... More >> Vanderbilt University Nashville, Tennessee, United States, 37232 Less << |
NCT00075101 | Leukemia | Phase 3 | Completed | - | United States, Tennessee ... More >> St. Jude Children Research Hospital Memphis, Tennessee, United States, 38105 Less << |
NCT00997412 | Myasthenia Gravis | Not Applicable | Unknown | May 2011 | - |
NCT02329964 | Muscle Relaxation | Phase 4 | Unknown | September 2016 | - |
NCT02329964 | - | Unknown | - | - | |
NCT02573519 | Diabetic Autonomic Neuropathy ... More >> Gastrointestinal Motility Disorder Diabetes Mellitus Change of Transit or Circulation Less << | Not Applicable | Recruiting | August 2019 | Denmark ... More >> Department of Hematology and Gastroenterology, Aarhus University Hospital Recruiting Aarhus, Denmark, 8000 Contact: Mette Winther Andersen +45 22635197 meteader@rm.dk Contact: Klaus Krogh, Professor +45 23385937 klaukrog@rm.dk Sub-Investigator: Anne-Mette Haase, P.hD. Sub-Investigator: Lotte Fynne, P.hD. Less << |
NCT03124355 | Postural Tachycardia Syndrome | Phase 1 | Recruiting | December 2020 | United States, Tennessee ... More >> Autonomic Dysfunction Center/ Vanderbilt University Medical Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Misty Hale, CCRP 615-322-2931 misty.hale@vanderbilt.edu Sub-Investigator: Bonnie K Black, RN Sub-Investigator: Luis E Okamoto, MD Sub-Investigator: David Robertson, MD Principal Investigator: Italo Biaggioni, MD Sub-Investigator: Alfredo Gamboa, MD Sub-Investigator: Cyndya A Shibao, MD Sub-Investigator: Andre Diedrich, MD, PhD Sub-Investigator: jorge Celedonio, MD Less << |
NCT02308124 | Orthostatic; Hypotension, Neur... More >>ogenic Less << | Phase 4 | Completed | - | Korea, Republic of ... More >> Seoul National University Hospital Seoul, Korea, Republic of Less << |
NCT00995722 | - | Terminated(Slow recruitment ra... More >>te) Less << | - | - | |
NCT02308124 | - | Completed | - | - | |
NCT03261570 | Postural Orthostatic Tachycard... More >>ia Syndrome (POTS) POTS Orthostatic Intolerance Less << | Early Phase 1 | Recruiting | September 1, 2021 | United States, New York ... More >> New York Medical College/Bradhurst building Recruiting Hawthorne, New York, United States, 10532 Contact: Courtney R. Terilli, RN. BSN 914-593-8888 courtney_terilli@nymc.edu Contact: Julian M. Stewart, M.D., Ph.D. 914-593-8888 julian_stewart@nymc.edu Principal Investigator: Julian M. Stewart, M.D., Ph.D. Sub-Investigator: Marvin S. Medow, Ph.D. Less << |
NCT02850276 | HIV Disease | Early Phase 1 | Completed | - | United States, New York ... More >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Less << |
NCT00535587 | Fibromyalgia | Phase 2 | Completed | - | United States, Oregon ... More >> Oregon Health & Science University Portland, Oregon, United States, 97219 Less << |
NCT00535587 | - | Completed | - | - | |
NCT02307526 | - | Completed | - | - | |
NCT03674541 | Preload Failure ... More >> Chronic Fatigue Syndrome Myalgic Encephalomyelitis Fibromyalgia Dyspnea Less << | Phase 3 | Not yet recruiting | October 15, 2019 | - |
NCT02893553 | Spinal Cord Injury ... More >> Autonomic Dysreflexia Baroreceptor Integrity Sympathetic Integrity Vagal Integrity Autonomic Integrity Hypotensive Cognitive Function Cerebral Blood Flow Blood Pressure Less << | Phase 2 | Recruiting | December 2019 | United States, New Jersey ... More >> Kessler Foundation Research Center Recruiting West Orange, New Jersey, United States, 07052 Contact: Alexander T Lombard, MS 973-324-3588 alombard@kesslerfoundation.org Contact: Caitlyn G Katzelnick, MS 973-324-3588 ckatzelnick@kesslerfoundation.org Principal Investigator: Jill M Wecht United States, New York James J Peters VAMC Recruiting Bronx, New York, United States, 10468 Contact: Matthew T Maher, MS 718-584-9000 ext 3122 Matthew.Maher@va.gov Principal Investigator: Jill M Wecht, EdD Less << |
NCT02307526 | Hypotension, Postural | Phase 2 | Completed | - | United States, New Jersey ... More >> Kessler Institute for Rehabilitation West Orange, New Jersey, United States, 07052 Less << |
NCT02364180 | - | Completed | - | - | |
NCT00409435 | Postural Tachycardia Syndrome | Not Applicable | Recruiting | February 2019 | United States, Minnesota ... More >> Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Toni Gehrking 507-284-0336 adc.research@mayo.edu Principal Investigator: Phillip A. Low, M.D. Less << |
NCT02364180 | Muscle Weakness | Not Applicable | Completed | - | United States, Ohio ... More >> University of Toledo, Health Science Campus Toledo, Ohio, United States, 43614 Less << |
NCT01370512 | Orthostatic Hypotension | Phase 2 | Recruiting | June 2019 | United States, Minnesota ... More >> Mayo Clinic in Rochester Recruiting Rochester, Minnesota, United States, 55905 Contact: Tonette Gehrking 507-284-0336 adc.research@mayo.edu Principal Investigator: Phillip A. Low, MD Less << |
NCT02227823 | Spinal Muscular Atrophy Type 3 | Phase 2 | Unknown | July 2017 | Belgium ... More >> Centre de référence des maladies neuromusculaire, Centre Hospitalier Régional de la Citadelle Recruiting Liège, Belgium, 4000 Contact: Stephanie Delstanche stephanie.delstanche@chrcitadelle.be Contact: Severine Denis severine.denis@chrcitadelle.be Principal Investigator: Stephanie Delstanche Less << |
NCT00953914 | Diabetes Complications | Not Applicable | Completed | - | Brazil ... More >> Hospital de Clínicas de Porto Alegre Porto Alegre, Rio Grande do Sul, Brazil Less << |
NCT02171988 | Postural Orthostatic Tachycard... More >>ia Syndrome Less << | Phase 4 | Completed | - | Korea, Republic of ... More >> Seoul National University Hospital Seoul, Korea, Republic of Less << |
NCT03510546 | Myasthenia Gravis | Phase 4 | Recruiting | August 31, 2021 | Denmark ... More >> Department of Neurology Aarhus University Hospital Recruiting Aarhus, Midtjylland, Denmark, 8000 Contact: Jan LS Thomsen, MD +45 7846 6647 jathms@rm.dk Contact: Henning Andersen, MD PhD DMSc +45 7846 6647 hennande@rm.dk Less << |
NCT03312244 | HIV-1-infection ... More >> CD4+ T Lymphocytopenia Immune Deficiency Immuno-senescence Less << | Phase 2 | Active, not recruiting | June 30, 2020 | Mexico ... More >> Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Tlalpan, Ciudad de México, Mexico, 14080 Less << |
NCT00276406 | Constipation ... More >>Diabetes Mellitus Colonic Transit Gastric Emptying Less << | Phase 1 Phase 2 | Completed | - | United States, Minnesota ... More >> Mayo Clinic Rochester, Minnesota, United States, 55905 Less << |
NCT03063515 | Diabetes Mellitus | Phase 1 | Recruiting | March 30, 2019 | United States, Florida ... More >> Diabetes Research Institute Recruiting Miami, Florida, United States, 33136 Contact: Maria Solano 305-243-6145 Principal Investigator: Maria del Pilar Solano, MD Less << |
NCT00276406 | - | Completed | - | - | |
NCT01415921 | - | Completed | - | - | |
NCT01993680 | Autonomic Disturbances in Park... More >>inson`s Disease Less << | Phase 2 | Unknown | January 2016 | Switzerland ... More >> University Hospital Zurich, Division of Neurology Zurich, ZH, Switzerland, 8091 Less << |
NCT01415921 | Heart Failure | Phase 2 | Completed | - | United States, New York ... More >> New York University Langone Medical Center New York, New York, United States, 10016 Less << |
NCT02941328 | Spinal Muscular Atrophy ... More >> SMA Kugelberg-Welander Disease Less << | Phase 2 | Completed | - | Netherlands ... More >> University Medical Center of Utrecht (UMCU) Utrecht, Netherlands, 3584 CX Less << |
NCT02357225 | Pompe Disease | Early Phase 1 | Terminated(The drug was ineffe... More >>ctive in improving function in Pompe's disease) Less << | - | United States, Florida ... More >> University of Florida Clinical Research Center Gainesville, Florida, United States, 32610 Less << |
NCT00518154 | HIV Infections | Phase 2 | Completed | - | Mexico ... More >> Departments of Immunology, and Infectious Diseases, INNSZ Mexico City, DF, Mexico, 14000 Less << |
NCT02157545 | - | Withdrawn(No eligible subjects... More >> identified. Study closed with IRB.) Less << | - | United States, Ohio ... More >> University of Toledo, Health Science Campus Toledo, Ohio, United States, 43614 Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
3.83mL 0.77mL 0.38mL |
19.15mL 3.83mL 1.91mL |
38.30mL 7.66mL 3.83mL |
|
Dissolving Methods |
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:
in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
|